KR101746867B1 - 당뇨 및 비만을 치료하기 위한 프테로신 화합물의 용도 - Google Patents

당뇨 및 비만을 치료하기 위한 프테로신 화합물의 용도 Download PDF

Info

Publication number
KR101746867B1
KR101746867B1 KR1020117019877A KR20117019877A KR101746867B1 KR 101746867 B1 KR101746867 B1 KR 101746867B1 KR 1020117019877 A KR1020117019877 A KR 1020117019877A KR 20117019877 A KR20117019877 A KR 20117019877A KR 101746867 B1 KR101746867 B1 KR 101746867B1
Authority
KR
South Korea
Prior art keywords
compound
delete delete
compounds
mice
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117019877A
Other languages
English (en)
Korean (ko)
Other versions
KR20110125642A (ko
Inventor
펑-린 수
싱-화 리우
빙-주안 우앙
Original Assignee
타이페이 메디컬 유니이버시티
내셔널 타이완 유니버시티
내셔널 칭화 유니버시티
디씨비-유에스에이 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타이페이 메디컬 유니이버시티, 내셔널 타이완 유니버시티, 내셔널 칭화 유니버시티, 디씨비-유에스에이 엘엘씨 filed Critical 타이페이 메디컬 유니이버시티
Publication of KR20110125642A publication Critical patent/KR20110125642A/ko
Application granted granted Critical
Publication of KR101746867B1 publication Critical patent/KR101746867B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020117019877A 2009-01-26 2010-01-26 당뇨 및 비만을 치료하기 위한 프테로신 화합물의 용도 Expired - Fee Related KR101746867B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14738209P 2009-01-26 2009-01-26
US61/147,382 2009-01-26
PCT/US2010/022129 WO2010085811A2 (en) 2009-01-26 2010-01-26 Use of pterosin compounds for treating diabetes and obesity

Publications (2)

Publication Number Publication Date
KR20110125642A KR20110125642A (ko) 2011-11-21
KR101746867B1 true KR101746867B1 (ko) 2017-06-14

Family

ID=42354647

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117019877A Expired - Fee Related KR101746867B1 (ko) 2009-01-26 2010-01-26 당뇨 및 비만을 치료하기 위한 프테로신 화합물의 용도

Country Status (10)

Country Link
US (1) US8633252B2 (enExample)
EP (1) EP2389171B1 (enExample)
JP (1) JP5640019B2 (enExample)
KR (1) KR101746867B1 (enExample)
CN (1) CN102333528B (enExample)
AU (1) AU2010206549B2 (enExample)
CA (1) CA2749931C (enExample)
NZ (1) NZ594236A (enExample)
TW (1) TWI522109B (enExample)
WO (1) WO2010085811A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555287A (zh) * 2013-06-19 2016-05-04 捷通国际有限公司 用于支持体重管理的基于植物的己酮糖激酶抑制剂
CN106831386A (zh) * 2015-12-04 2017-06-13 江西中医药大学 新型蕨素类化合物在治疗糖尿病的应用
CN105878220B (zh) * 2016-04-21 2019-02-05 广州市爱菩新医药科技有限公司 倍半萜类化合物在制备防治高血脂药物中的应用
CN107232497A (zh) * 2017-06-01 2017-10-10 河北农业大学 一种具有降血脂功能的膨化食品及其制备方法
EP3639817B1 (en) * 2017-06-16 2024-10-09 Korpharm Co., Ltd. Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases
CN108576355B (zh) * 2018-03-27 2021-11-09 百色学院 一种蕨菜多糖含片及其制备方法
CN110156738B (zh) * 2019-06-26 2023-01-03 中北大学 一种伊鲁烷型倍半萜反应中间体及天然产物的全合成方法
KR102767836B1 (ko) * 2020-12-14 2025-02-14 주식회사 지에이치팜 프테로신 화합물 및 이의 유도체를 유효성분으로 포함하는 pka 관련 질환 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075338A1 (en) * 2001-07-27 2005-04-07 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
WO2008089310A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745104A (en) * 1985-04-15 1988-05-17 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
US4849410A (en) * 1985-04-15 1989-07-18 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
JPS63146839A (ja) 1986-12-11 1988-06-18 Toa Nenryo Kogyo Kk プテロシン系化合物を含んで成る制癌剤
JPH02237932A (ja) * 1989-03-10 1990-09-20 Yokichi Mochizuki 結石等の治療剤
US5439936A (en) * 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
CA2135474C (en) * 1993-04-07 1998-11-10 Shingo Yano Thiazolidine derivatives and pharmaceutical compositions containing the same
WO1998025907A1 (en) 1996-12-12 1998-06-18 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
FR2777566B1 (fr) * 1998-04-15 2003-02-21 Synthelabo Derives d'azacycloalcanes, leur preparation et leur application en therapeutique
SK288217B6 (sk) * 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
DE10142668A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142666A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6797287B2 (en) * 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
CN100544715C (zh) * 2002-04-30 2009-09-30 尤尼根制药公司 作为治疗剂的包含无取代b环类黄酮和黄烷混合物的组合物
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
US7960369B2 (en) * 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
CA2516710A1 (en) * 2003-02-26 2004-09-10 Unigen Pharmaceuticals, Inc. Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions
JP2007510651A (ja) * 2003-11-04 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合フェニルアラニン誘導体
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
UA92150C2 (ru) * 2004-06-04 2010-10-11 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств
JP2008522972A (ja) * 2004-12-06 2008-07-03 レリアント ファーマスーティカルズ インコーポレイテッド 脂肪酸エステルを有する安定性フェノフィブラート組成物
FR2880885B1 (fr) * 2005-01-14 2009-01-30 Merck Sante Soc Par Actions Si Derives d'acide phenylbenzoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
CA2595835A1 (en) * 2005-02-05 2006-08-10 Astrazeneca Ab Chemical compounds
AU2006291234A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075338A1 (en) * 2001-07-27 2005-04-07 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
WO2008089310A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity

Also Published As

Publication number Publication date
WO2010085811A2 (en) 2010-07-29
EP2389171A4 (en) 2012-10-10
AU2010206549A9 (en) 2016-08-25
JP2012515801A (ja) 2012-07-12
AU2010206549B2 (en) 2016-08-25
TWI522109B (zh) 2016-02-21
CN102333528A (zh) 2012-01-25
KR20110125642A (ko) 2011-11-21
NZ594236A (en) 2014-08-29
CA2749931A1 (en) 2010-07-29
EP2389171B1 (en) 2016-03-30
US20100190732A1 (en) 2010-07-29
US8633252B2 (en) 2014-01-21
CA2749931C (en) 2018-03-06
EP2389171A2 (en) 2011-11-30
CN102333528B (zh) 2013-12-18
WO2010085811A9 (en) 2010-11-04
AU2010206549A1 (en) 2011-08-11
TW201039836A (en) 2010-11-16
JP5640019B2 (ja) 2014-12-10

Similar Documents

Publication Publication Date Title
KR101746867B1 (ko) 당뇨 및 비만을 치료하기 위한 프테로신 화합물의 용도
Kuo et al. RETRACTED ARTICLE: Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade
CA2694881C (en) The application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression
KR100711028B1 (ko) 향나무 추출물 또는 세드롤을 포함하는 비만 및 제2형당뇨병 예방 및 치료용 조성물
JP2000154151A (ja) 免疫抑制剤
CN103804442B (zh) 黄酮醇衍生物及其医药用途
CN103585166B (zh) 黄醇酮衍生物的医药用途
ES2255869B1 (es) Composiciones de productos naturales para el tratamiento de la diabetes.
CN103420805B (zh) 天麻中具有神经细胞保护活性的多聚苄类衍生物
WO2009128583A1 (en) Novel compounds and fractions for enhancing ucp expression
KR100697235B1 (ko) 관동화 추출물 또는 투실라곤을 포함하는 비만 및 제2형당뇨병 예방 및 치료용 조성물
US10064908B2 (en) Method for preventing, improving or treating liver disease
CN117659105A (zh) 一种愈创木烷型倍半萜苷单体化合物及其制备方法和用途
CN109875985B (zh) 一种毛白饭树提取物及其在制备抗骨质疏松药物中的应用
KR102113563B1 (ko) 하이드란제놀을 유효성분으로 하는 근육 질환 예방 및 치료, 근기능 개선, 또는 운동수행능력 향상용 조성물
Chen et al. The extracts of small-leaved kudingcha as potential modulators of β-cells for the therapy of type 2 diabetes mellitus
CN104546875A (zh) 三萜皂苷衍生物及其医药用途
CN115785190A (zh) 化合物Caffarolide A及其药物组合物与其在制药中的应用
CN116509918A (zh) 三种天然产物组合在制备治疗非酒精性脂肪肝药物中的应用
Kato et al. Inhibitory effects of Senkyu-chacho-san and Cnidii Rhizoma on catechol-O-methyltransferase
CN110003230A (zh) 克罗烷型二萜化合物及其药物组合物和其应用
CN1678300A (zh) 可用于治疗慢性髓细胞性白血病的药物组合物
KR20070001326A (ko) 핵수용체 피피에이알감마의 신규한 리간드
CN105326819A (zh) Guttiferone K的医药用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200608

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200608